Alkermes Plc Is a Buy; Strong Momentum from Option Traders

 Alkermes Plc Is a Buy; Strong Momentum from Option Traders

In today’s session Alkermes Plc (ALKS) registered an unusually high (1,001) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the February, 2017 call, expecting serious ALKS increase. With 1,001 contracts traded and 2374 open interest for the Feb, 17 contract, it seems this is a quite bullish bet. The option with symbol: ALKS170217C00060000 closed last at: $2.55 or 8.9% down. About 692,909 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 51.74% since March 31, 2016 and is uptrending. It has outperformed by 49.22% the S&P500.

Analysts await Alkermes Plc (NASDAQ:ALKS) to report earnings on November, 3. They expect $-0.20 EPS, up 52.38% or $0.22 from last year’s $-0.42 per share. After $-0.18 actual EPS reported by Alkermes Plc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Out of 8 analysts covering Alkermes (NASDAQ:ALKS), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Alkermes has been the topic of 16 analyst reports since September 1, 2015 according to StockzIntelligence Inc. The stock of Alkermes Plc (NASDAQ:ALKS) has “Outperform” rating given on Friday, October 21 by Leerink Swann. The firm earned “Outperform” rating on Thursday, January 21 by Leerink Swann. On Friday, July 29 the stock rating was maintained by Jefferies with “Buy”. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Market Perform” rating by Cowen & Co on Tuesday, July 26. Morgan Stanley upgraded the stock to “Overweight” rating in Tuesday, September 1 report. Jefferies maintained the shares of ALKS in a report on Friday, October 21 with “Buy” rating. As per Friday, January 22, the company rating was maintained by UBS. On Thursday, January 21 the stock rating was downgraded by Cowen & Co to “Market Perform”. The stock of Alkermes Plc (NASDAQ:ALKS) has “Overweight” rating given on Wednesday, July 13 by Barclays Capital. The firm has “Overweight” rating given on Friday, October 21 by JP Morgan.

According to Zacks Investment Research, “Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes’ pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.”

Insitutional Activity: The institutional sentiment increased to 0.96 in Q2 2016. Its up 0.25, from 0.71 in 2016Q1. The ratio is positive, as 31 funds sold all Alkermes Plc shares owned while 75 reduced positions. 34 funds bought stakes while 68 increased positions. They now own 135.77 million shares or 0.84% less from 136.92 million shares in 2016Q1.
Bb&T Corp accumulated 0.01% or 10,199 shares. Royal Retail Bank Of Canada owns 27,922 shares or 0% of their US portfolio. Cubist Systematic Strategies Ltd Llc owns 6,178 shares or 0.02% of their US portfolio. Mackenzie Financial has 0% invested in the company for 5,257 shares. M&T Savings Bank Corporation accumulated 5,021 shares or 0% of the stock. Opus Point Prtnrs Management Limited owns 82,858 shares or 3.46% of their US portfolio. Moreover, Epoch Prtnrs Inc has 0.04% invested in Alkermes Plc (NASDAQ:ALKS) for 268,052 shares. Us Financial Bank De has 531 shares for 0% of their US portfolio. Marshall Wace Limited Liability Partnership has 0.17% invested in the company for 454,490 shares. Moreover, Amer Century Incorporated has 0% invested in Alkermes Plc (NASDAQ:ALKS) for 13,347 shares. Roanoke Asset Ny accumulated 104,962 shares or 2.1% of the stock. Wells Fargo & Mn last reported 245,095 shares in the company. Capital Fund Management has 156,406 shares for 0.06% of their US portfolio. Teacher Retirement Sys Of Texas last reported 10,706 shares in the company. Kbc Group Nv last reported 0.01% of its portfolio in the stock.

Alkermes Public Limited Company is a biopharmaceutical company. The company has a market cap of $8.21 billion. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

ALKS Company Profile

Alkermes Public Limited Company, incorporated on May 4, 2011, is a biopharmaceutical company. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. The Company’s products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. The Company’s product platforms include injectable extended release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

More recent Alkermes Plc (NASDAQ:ALKS) news were published by: Businesswire.com which released: “Alkermes plc Reports Third Quarter 2016 Financial Results” on November 02, 2016. Also Fool.com published the news titled: “Why Alkermes PLC Skyrocketed Today” on October 21, 2016. Investingnews.com‘s news article titled: “5 Top NASDAQ Biotech Stocks: Alkermes PLC Leads” with publication date: October 24, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment